Blog
About

7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?

      Health affairs (Project Hope)

      economics, Value of Life, United States, drug effects, Plasmodium malariae, Models, Econometric, prevention & control, drug therapy, Malaria, International Cooperation, Institute of Medicine (U.S.), Humans, trends, Health Services Needs and Demand, Global Health, Financing, Organized, Drug Therapy, Combination, Drug Resistance, Drug Costs, therapeutic use, pharmacology, Artemisinins, Antimalarials, Animals

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With parasite resistance to chloroquine increasing rapidly in many parts of the world, there is greater recognition of the need for a globally coordinated strategy to ensure that artemisinins are not used as monotherapy, which has the potential to cut short their useful therapeutic life. We find that even a partial subsidy could delay the emergence of resistance and that a delay in implementing a subsidy for ACTs could facilitate the emergence of resistance and lower the economic value of ACTs.

          Related collections

          Author and article information

          Journal
          16522574
          10.1377/hlthaff.25.2.325

          Comments

          Comment on this article